Uranium Royalty [UROY] vs Cameco [CCJ] Detailed Stock Comparison
Uranium Royalty
NASDAQ
Loading...
Cameco
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Uranium Royalty wins in 5 metrics, Cameco wins in 13 metrics, with 0 ties. Cameco appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Uranium Royalty | Cameco | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 57.67 | 86.01 | Uranium Royalty |
| Price-to-Book Ratio | 1.17 | 4.94 | Uranium Royalty |
| Debt-to-Equity Ratio | 0.07 | 14.94 | Uranium Royalty |
| PEG Ratio | -0.40 | 64.87 | Uranium Royalty |
| EV/EBITDA | -74.37 | 35.16 | Uranium Royalty |
| Profit Margin (TTM) | -36.26% | 14.95% | Cameco |
| Operating Margin (TTM) | -19.33% | 17.82% | Cameco |
| EBITDA Margin (TTM) | N/A | 17.82% | N/A |
| Return on Equity | -1.98% | 8.25% | Cameco |
| Return on Assets (TTM) | -0.94% | 3.95% | Cameco |
| Free Cash Flow (TTM) | $-33.21M | $693.65M | Cameco |
| Dividend Yield | N/A | 0.16% | N/A |
| 1-Year Return | 32.85% | 93.10% | Cameco |
| Price-to-Sales Ratio (TTM) | 22.19 | 9.34 | Cameco |
| Enterprise Value | $228.94M | $24.40B | Cameco |
| EV/Revenue Ratio | 20.23 | 9.42 | Cameco |
| Gross Profit Margin (TTM) | 14.12% | 29.31% | Cameco |
| Revenue per Share (TTM) | $0 | $8 | Cameco |
| Earnings per Share (Diluted) | $-0.03 | $0.89 | Cameco |
| Beta (Stock Volatility) | 1.83 | 1.26 | Cameco |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Uranium Royalty vs Cameco Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Uranium Royalty | -0.94% | 2.32% | 7.29% | 37.31% | 6.85% | 12.29% |
| Cameco | 0.79% | 1.92% | 1.57% | 53.54% | 52.95% | 46.41% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Uranium Royalty | 32.85% | 0.73% | -21.88% | -21.88% | -21.88% | -21.88% |
| Cameco | 93.10% | 199.96% | 632.21% | 435.55% | 208.07% | 211.97% |
Performance & Financial Health Analysis: Uranium Royalty vs Cameco
| Metric | UROY | CCJ |
|---|---|---|
| Market Information | ||
| Market Cap | $346.12M | $33.33B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,944,470 | 4,502,610 |
| 90 Day Avg. Volume | 3,182,690 | 5,048,627 |
| Last Close | $2.62 | $76.97 |
| 52 Week Range | $1.43 - $3.30 | $35.00 - $80.32 |
| % from 52W High | -20.33% | -4.17% |
| All-Time High | $5.95 (Oct 25, 2021) | $80.32 (Jul 29, 2025) |
| % from All-Time High | -55.97% | -4.17% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.62% | 0.47% |
| Quarterly Earnings Growth | -0.62% | 7.91% |
| Financial Health | ||
| Profit Margin (TTM) | -0.36% | 0.15% |
| Operating Margin (TTM) | -0.19% | 0.18% |
| Return on Equity (TTM) | -0.02% | 0.08% |
| Debt to Equity (MRQ) | 0.07 | 14.94 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.21 | $15.48 |
| Cash per Share (MRQ) | $0.15 | $1.65 |
| Operating Cash Flow (TTM) | $-15,693,245 | $839.92M |
| Levered Free Cash Flow (TTM) | $-23,004,970 | $529.62M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.16% |
| Last 12-Month Dividend | N/A | $0.11 |
Valuation & Enterprise Metrics Analysis: Uranium Royalty vs Cameco
| Metric | UROY | CCJ |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 57.67 | 86.01 |
| Forward P/E | -39.43 | 64.87 |
| PEG Ratio | -0.40 | 64.87 |
| Price to Sales (TTM) | 22.19 | 9.34 |
| Price to Book (MRQ) | 1.17 | 4.94 |
| Market Capitalization | ||
| Market Capitalization | $346.12M | $33.33B |
| Enterprise Value | $228.94M | $24.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 20.23 | 9.42 |
| Enterprise to EBITDA | -74.37 | 35.16 |
| Risk & Other Metrics | ||
| Beta | 1.83 | 1.26 |
| Book Value per Share (MRQ) | $2.21 | $15.48 |
Financial Statements Comparison: Uranium Royalty vs Cameco
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | UROY | CCJ |
|---|---|---|
| Revenue/Sales | $4.69M | $789.43M |
| Cost of Goods Sold | $4.03M | $519.30M |
| Gross Profit | $662,000 | $270.14M |
| Research & Development | N/A | $13.98M |
| Operating Income (EBIT) | $-980,000 | $188.03M |
| EBITDA | $-859,000 | $221.25M |
| Pre-Tax Income | $-1.09M | $123.16M |
| Income Tax | $66,000 | $53.41M |
| Net Income (Profit) | $-1.16M | $69.75M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | UROY | CCJ |
|---|---|---|
| Cash & Equivalents | $12.94M | $361.47M |
| Total Current Assets | $238.16M | $1.50B |
| Total Current Liabilities | $1.02M | $554.57M |
| Long-Term Debt | $157,000 | $995.74M |
| Total Shareholders Equity | $294.89M | $6.49B |
| Retained Earnings | $17.23M | $3.17B |
| Property, Plant & Equipment | $189,000 | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | UROY | CCJ |
|---|---|---|
| Operating Cash Flow | $2.92M | $359.25M |
| Capital Expenditures | $0 | $-56.44M |
| Free Cash Flow | $3.28M | $53.73M |
| Debt Repayment | $19.28M | $-285.84M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | UROY | CCJ |
|---|---|---|
| Shares Short | 13.29M | 18.44M |
| Short Ratio | 4.11 | 3.27 |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 3,944,470 | 4,502,610 |
| Average Daily Volume (90 Day) | 3,182,690 | 5,048,627 |
| Shares Outstanding | 133.64M | 435.31M |
| Float Shares | 112.59M | 434.23M |
| % Held by Insiders | 0.16% | 0.00% |
| % Held by Institutions | 0.28% | 0.73% |
Dividend Analysis & Yield Comparison: Uranium Royalty vs Cameco
| Metric | UROY | CCJ |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.11 |
| Last 12-Month Dividend Yield | N/A | 0.16% |
| 3-Year Avg Annual Dividend | N/A | $0.10 |
| 3-Year Avg Dividend Yield | N/A | 0.25% |
| 3-Year Total Dividends | N/A | $0.29 |
| Ex-Dividend Date | N/A | Nov 27, 2024 |